Search articles, concepts, and chapters
Section III · Management
Shields' Textbook of Glaucoma, 6th edition
Showing 1–20 of 1,392 articles
Rocks Madeline C, Dossantos Jason, Tran Hoang-Viet et al.
This study found OMNI canaloplasty with or without a Hydrus microstent during cataract surgery yielded comparable IOP, medication, and success rates at one year, suggesting the microstent may not add significant benefit.
Yuma Masaki, Jujo Tatsuya, Sato Keiji et al.
This study found longer iris length is a significant risk factor for reverse pupillary block after intraocular lens fixation surgery, aiding surgical planning and patient counseling.
Fabian Ekkehard, Janeková Andrea, de Arriba Palomero Pablo et al.
This study found Z-HYALCOAT non-inferior to HEALON EndoCoat for cataract surgery, showing similar IOP spikes, endothelial cell loss, and overall safety. This offers clinicians another comparable OVD option.
Miller Kevin M, Aboughaida Ali, Dyk David et al.
This study compared phacoemulsification systems, finding UNITY® had 44% lower occlusion break surge than CENTURION®. This reduces intraocular pressure fluctuations, potentially improving safety and confidence in complex cataract surgery.
Okada Yo, Mori Kazuhiko, Yoshii Kengo et al.
PreserFlo alone was safe for corneal endothelium across glaucoma types, but combining it with cataract surgery increased endothelial cell loss, especially in pseudoexfoliation glaucoma, impacting surgical planning.
Klabe Karsten, Werth Jan Philipp, Kaymak Hakan et al.
This study found the Preserflo MicroShunt effectively and safely lowered eye pressure long-term in open-angle glaucoma patients, including those with combined cataract surgery or pseudophakia, supporting its real-world use.
Vasavada Shail, Dwivedi Shyamal, Vasavada Vaishali et al.
This study found that low intraoperative IOP (20mmHg) during cataract surgery in diabetic retinopathy patients improved macular and optic nerve perfusion, suggesting a beneficial clinical effect.
Ang Bryan Chin Hou, Betzler Bjorn Kaijun, Sim Jackie Jia Lin et al.
Phaco-Hydrus in NTG eyes sustainedly reduced glaucoma medication burden over 36 months, without significant IOP reduction. This suggests its role is primarily medication reduction, not IOP lowering.
Tan Nicholas E, Young Cara E Capitena, Seibold Leonard K
This review found trabecular bypass stents and canaloplasty effectively lower IOP and medication needs in glaucoma, with stents having more long-term data but canaloplasty offering similar efficacy without implant issues.
Mieno Hiroki, Mori Kazuhiko, Kano Kiyoshi et al.
PRESERFLO MicroShunt effectively lowered IOP and medication use in a large Japanese cohort. High preoperative medication use and prior cataract surgery were risk factors for failure, guiding patient selection.
Wang Jin, Hu Keyu, Liu Zijian et al.
This study found lens-related angle-closure glaucoma patients had higher 5-year reoperation rates after Phaco-GSL than primary angle-closure, emphasizing tailored management for these high-risk individuals.
Xie Bin, Yang Zefeng, Wang Zhixuan et al.
Goniotomy and phacogoniotomy are effective, safe, and widely applicable glaucoma surgeries, especially valuable in resource-limited settings due to their non-device-built nature.
Orenc Pinar, Kuçukbezirci Guldeniz Usta, Gungel Hulya
This study found combined phacoemulsification and HFDS successfully lowered IOP. Postoperative AS-OCT showed angle widening, with 750-µm posterior angle measurements potentially indicating surgical success, aiding long-term glaucoma follow-up.
Murthy Gowri Jayadev, Cn Supritha, Mr Praveen et al.
Toric IOLs in combined cataract and glaucoma surgery provide accurate astigmatism correction and good vision, comparable to standalone cataract surgery, when using a standardized technique.
Xiong Kun, Wang Yachen, Yu Bo et al.
This study found that combined cataract surgery and goniosynechialysis effectively lowered eye pressure in angle-closure glaucoma, regardless of initial synechiae extent, suggesting broad applicability.
Gupta Sanchay, Ziari Melody, Blieden Lauren S
This review highlights that intraoperative OCT enhances surgical decision-making and outcomes in glaucoma surgery, offering real-time visualization for procedures like tube shunts and MIGS.
Tan Jeremy C K, Clement Colin, Healey Paul et al.
This study found no significant difference in long-term glaucoma control between Hydrus and iStent inject combined with cataract surgery, with over 40% achieving success. Both are comparable options for patients.
Guarro Mercè, Goñi Guarro Idoia, López Elena et al.
Wavefront-shaping IOLs in early/moderate glaucoma showed good vision, contrast, and low disturbances, offering a viable option for spectacle independence in these patients.
Wortmann Charlotte, Backes Johanna, Rothaus Kai et al.
Cataract surgery with IOLs in children with JIA/ANA-positive uveitis improved vision, but careful uveitis control and tailored surgery are crucial for good outcomes and managing complications like glaucoma.
Ahmed Yasmeen, Erichsen Jesper Høiberg, Ahmadzadeh Afrouz et al.
This study compared inflammation and macular thickness after trabeculectomy vs. phacoemulsification. Both procedures caused similar early inflammation, but phacoemulsification led to a significantly greater and more persistent increase in macular thickness.
The overall 2-year failure rate for trabeculectomy was 50.6%, for tube shunt surgery was 52.1%, for goniotomy was 53.3%, and for canaloplasty was 49.0% among 2483 eyes with secondary glaucoma aged 18 to 40 years.
Minimally invasive glaucoma surgery (MIGS) accounted for nearly one in five of the glaucoma surgeries recorded in young patients with secondary glaucoma, with approximately half of cases remaining failure-free at 2 years.
In uveitic glaucoma, the 2-year failure rates were 56.0% for trabeculectomy, 45.6% for tube shunt surgery, 55.1% for goniotomy, and 35.9% for canaloplasty.
In primary open-angle glaucoma (POAG) patients, iTrack ab-interno canaloplasty and iStent trabecular micro-bypass implantation showed no statistically significant differences in effectiveness outcomes.
In primary open-angle glaucoma (POAG) patients, both iTrack ab-interno canaloplasty and iStent trabecular micro-bypass implantation had favourable safety profiles with infrequent and self-limited complications, no sight-threatening events, and low reoperation rates.
More eyes were medication-free in the iTrack ab-interno canaloplasty group (42%) compared to the iStent trabecular micro-bypass implantation group (29%) in primary open-angle glaucoma (POAG) patients (p=0.029).
In primary open-angle glaucoma (POAG) patients, mean intraocular pressure (IOP) and medication usage decreased from 17.3 ± 4.2 mmHg and 2.0 ± 1.1 at baseline to 14.2 ± 3.5 mmHg and 1.3 ± 1.1 in the iStent trabecular micro-bypass group (p<0.001) over a mean follow-up of 27.2 ± 14.5 months.
In primary open-angle glaucoma (POAG) patients, mean intraocular pressure (IOP) and medication usage decreased from 16.9 ± 5.0 mmHg and 2.0 ± 1.1 at baseline to 14.3 ± 3.4 mmHg and 1.1 ± 1.3 in the iTrack ab-interno canaloplasty group (p<0.001) over a mean follow-up of 20.3 ± 7.7 months.
PreserFlo™ MicroShunt implantation significantly reduced mean intraocular pressure (IOP) from 24.29±6.05 mmHg to 17.95±8.22 mmHg (P < 0.001) in 34 eyes from 27 children (mean age 4.9 ± 3.6 y) with refractory childhood glaucoma.
PreserFlo™ MicroShunt implantation significantly reduced mean IOP-lowering medication numbers from 3.0±0.0 to 0.9±1.3 (P < 0.001) in 34 eyes from 27 children (mean age 4.9 ± 3.6 y) with refractory childhood glaucoma.
Overall success of PreserFlo™ MicroShunt implantation was 61.70% in 34 eyes from 27 children with refractory childhood glaucoma, with 50% achieving complete success (IOP <21 mmHg and ≥25% IOP reduction without medications) at an average follow-up time of 13.92±4.85 months.
The survival rates of PreserFlo™ MicroShunt implantation in refractory childhood glaucoma declined to 53% at 12 months and 33% at 24 months in 34 eyes from 27 children.